Calidi Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Calidi Biotherapeutics, Inc. (CLDI) on August 29, 2025. The Company is incorporated in Delaware and operates as an emerging growth company. The report primarily serves to disclose a Regulation FD presentation made available on the Company's website on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate presentation rather than a financial statement report.
Material Changes
No material financial changes or operational updates are detailed within the text of this 8-K filing. The sole material event reported is the release of an updated corporate presentation (Exhibit 99.1).
Guidance, Outlook, and Risks
Management commentary, guidance, and specific risk factors are contained within the furnished presentation (Exhibit 99.1) and are not explicitly detailed in the body of this 8-K. The filing includes standard disclaimers stating that the information is furnished, not "filed," and shall not be deemed incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached presentation) for specific clinical updates, financial outlook, and strategic guidance.
- Verify the Company's status as an emerging growth company and its implications for financial reporting standards.
- Confirm the trading symbol (CLDI) and exchange (NYSE American LLC) for current market data.
- Note that this 8-K does not contain audited financial data; refer to the most recent 10-K or 10-Q for detailed financial metrics.